Top View
- (INN) for Biological and Biotechnological Substances
- Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
- Anti-IL-4Rα (Dupilumab), Human Igg4 Antibody
- Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma
- Dupixent® (Dupilumab) Smpc Updated with Long-Term Data Reinforcing Well-Established Safety Profile in Adults with Moderate-To-Severe Atopic Dermatitis
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Matching-Adjusted Indirect Comparison of Benralizumab Versus Interleukin-5 Inhibitors: Systematic Review
- New Initiators to Asthma Biologics: Apre/Post Analysis of Utilization Patterns, Total Cost of Care, and H.V
- Dupixent, INN-Dupilumab
- Biologics in Pediatric Psoriasis and Atopic Dermatitis: Revolutionizing the Treatment Landscape
- Dupilumab Factsheet Dupilumab, Also Known As Dupixent®, Is a New Treatment for Severe Eczema
- Download the PDF Version
- COVID-19 Vaccine Information for People on an Immunosuppressive Or Biological Treatment
- Download the PDF Version
- New Drugs Reviewed for P&T Meeting September 28Th, 2017
- Anti-IL-4Ralpha Monoclonal Antibody Dupilumab
- Role of IL-23 Neutralization in Psoriasis – Insights from a 2 Mechanistic PK/PD Model and Meta-Analysis of Clinical Data
- Development of Sézary Syndrome Following the Administration of Dupilumab
- New Dupixent® (Dupilumab)
- Az Immunfarmakológia Alapjai És Immuntoxikológia
- Infections in Dupilumab Clinical Trials in Atopic Dermatitis: a Comprehensive Pooled Analysis
- Doctor Daveluy
- Monoclonal Antibodies in Type 2 Asthma: a Systematic Review and Network Meta- Analysis Ahmed Edris1, Silke De Feyter1,2, Tania Maes2, Guy Joos2 and Lies Lahousse1*
- Indirect Comparison of Efficacy of Dupilumab Versus Mepolizumab and Omalizumab for Severe Type 2 Asthma
- Prescribing Information
- Long-Standing Dermatitis Treated with Dupilumab with Subsequent Progression to Cutaneous T-Cell Lymphoma
- Dupilumab) Injection, for Subcutaneous Use Every Other Week
- Economic Evaluation of Dupilumab for the Treatment of Moderate-To-Severe Atopic Dermatitis in Adults
- Patient Information DUPIXENT
- Indirect Comparison of Efficacy of Dupilumab Versus Mepolizumab and Omalizumab for Severe Type 2 Asthma
- FDA Briefing Document Pulmonary-Allergy Drugs Advisory
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- Corporate Presentation Template
- A Mathematical Model to Identify Optimal Combinations of Drug
- (INN) for Biological and Biotechnological Substances
- CV Blauvelt March 2021
- 20.201 Mechanisms of Drug Actions Sarilumab Case Study
- Refractory Pediatric Psoriasis and Atopic Dermatitis: the Importance of Therapeutical Adherence and Biological Management
- Specialty Pipeline Update
- Monoclonal Antibodies in Type 2 Asthma: a Systematic Review and Network Meta- Analysis Ahmed Edris1, Silke De Feyter1,2, Tania Maes2, Guy Joos2 and Lies Lahousse1*
- WO 2015/105926 Al 16 July 2015 (16.07.2015) P O PCT
- Cowen Healthcare Conference March 2017
- Antibodies to Watch in 2018